Published in Neuromuscul Disord on July 01, 2004
Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial. JAMA (2012) 1.40
Molecular Insights into the Local Anesthetic Receptor within Voltage-Gated Sodium Channels Using Hydroxylated Analogs of Mexiletine. Front Pharmacol (2012) 0.93
Searching for novel anti-myotonic agents: pharmacophore requirement for use-dependent block of skeletal muscle sodium channels by N-benzylated cyclic derivatives of tocainide. Neuromuscul Disord (2011) 0.86
Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery. Front Pharmacol (2016) 0.86
Combined modifications of mexiletine pharmacophores for new lead blockers of Na(v)1.4 channels. Biophys J (2013) 0.85
Late Na(+) current and protracted electrical recovery are critical determinants of the aging myopathy. Nat Commun (2015) 0.85
Taurine: the appeal of a safe amino acid for skeletal muscle disorders. J Transl Med (2015) 0.85
Increased sodium channel use-dependent inhibition by a new potent analogue of tocainide greatly enhances in vivo antimyotonic activity. Neuropharmacology (2016) 0.83
In vivo evaluation of antimyotonic efficacy of β-adrenergic drugs in a rat model of myotonia. Neuropharmacology (2012) 0.79
Sodium channel slow inactivation as a therapeutic target for myotonia congenita. Ann Neurol (2015) 0.79
Mutation of Vps54 causes motor neuron disease and defective spermiogenesis in the wobbler mouse. Nat Genet (2005) 1.99
Ion channel pharmacology. Neurotherapeutics (2007) 1.42
Enhanced dystrophic progression in mdx mice by exercise and beneficial effects of taurine and insulin-like growth factor-1. J Pharmacol Exp Ther (2003) 1.41
Therapeutic approaches to ion channel diseases. Adv Genet (2008) 1.32
Redox homeostasis, oxidative stress and disuse muscle atrophy. J Physiol (2011) 1.25
The metalloprotease disintegrin ADAM8. Processing by autocatalysis is required for proteolytic activity and cell adhesion. J Biol Chem (2002) 1.23
A multidisciplinary evaluation of the effectiveness of cyclosporine a in dystrophic mdx mice. Am J Pathol (2005) 1.10
Molecular determinants of differential pore blocking of kidney CLC-K chloride channels. EMBO Rep (2004) 1.09
Proteome analysis of the dystrophin-deficient MDX diaphragm reveals a drastic increase in the heat shock protein cvHSP. Proteomics (2006) 1.06
Recovery of the soleus muscle after short- and long-term disuse induced by hindlimb unloading: effects on the electrical properties and myosin heavy chain profile. Neurobiol Dis (2005) 1.06
Change of chloride ion channel conductance is an early event of slow-to-fast fibre type transition during unloading-induced muscle disuse. Brain (2002) 1.06
Antioxidant treatment of hindlimb-unloaded mouse counteracts fiber type transition but not atrophy of disused muscles. Pharmacol Res (2010) 1.05
Activation and inhibition of kidney CLC-K chloride channels by fenamates. Mol Pharmacol (2005) 1.05
Recent advances in the pathogenesis and drug action in periodic paralyses and related channelopathies. Front Pharmacol (2011) 1.05
Carbonic anhydrase inhibitors are specific openers of skeletal muscle BK channel of K+-deficient rats. FASEB J (2004) 1.04
Gentamicin treatment in exercised mdx mice: Identification of dystrophin-sensitive pathways and evaluation of efficacy in work-loaded dystrophic muscle. Neurobiol Dis (2008) 1.03
Decrease in resting calcium and calcium entry associated with slow-to-fast transition in unloaded rat soleus muscle. FASEB J (2003) 1.02
Molecular switch for CLC-K Cl- channel block/activation: optimal pharmacophoric requirements towards high-affinity ligands. Proc Natl Acad Sci U S A (2008) 1.02
Different flecainide sensitivity of hNav1.4 channels and myotonic mutants explained by state-dependent block. J Physiol (2003) 1.02
Patterns of myocardial histogenesis as revealed by mouse chimeras. Dev Biol (2005) 1.02
Disuse of rat muscle in vivo reduces protein kinase C activity controlling the sarcolemma chloride conductance. J Physiol (2007) 1.01
Molecular requisites for drug binding to muscle CLC-1 and renal CLC-K channel revealed by the use of phenoxy-alkyl derivatives of 2-(p-chlorophenoxy)propionic acid. Mol Pharmacol (2002) 1.01
Multiple pathological events in exercised dystrophic mdx mice are targeted by pentoxifylline: outcome of a large array of in vivo and ex vivo tests. J Appl Physiol (1985) (2009) 1.00
Structure-affinity relationship study on N-[4-(4-arylpiperazin-1-yl)butyl]arylcarboxamides as potent and selective dopamine D(3) receptor ligands. J Med Chem (2002) 1.00
Is oxidative stress a cause or consequence of disuse muscle atrophy in mice? A proteomic approach in hindlimb-unloaded mice. Exp Physiol (2009) 0.99
Investigations of pharmacologic properties of the renal CLC-K1 chloride channel co-expressed with barttin by the use of 2-(p-Chlorophenoxy)propionic acid derivatives and other structurally unrelated chloride channels blockers. J Am Soc Nephrol (2004) 0.99
Fluvastatin and atorvastatin affect calcium homeostasis of rat skeletal muscle fibers in vivo and in vitro by impairing the sarcoplasmic reticulum/mitochondria Ca2+-release system. J Pharmacol Exp Ther (2007) 0.98
Major channels involved in neuropsychiatric disorders and therapeutic perspectives. Front Genet (2013) 0.97
Mechanisms of block of muscle type CLC chloride channels (Review). Mol Membr Biol (2003) 0.95
Fiber type-related changes in rat skeletal muscle calcium homeostasis during aging and restoration by growth hormone. Neurobiol Dis (2005) 0.94
Different ability of clenbuterol and salbutamol to block sodium channels predicts their therapeutic use in muscle excitability disorders. Mol Pharmacol (2003) 0.93
The KATP channel is a molecular sensor of atrophy in skeletal muscle. J Physiol (2010) 0.93
Molecular Insights into the Local Anesthetic Receptor within Voltage-Gated Sodium Channels Using Hydroxylated Analogs of Mexiletine. Front Pharmacol (2012) 0.93
First evaluation of the potential effectiveness in muscular dystrophy of a novel chimeric compound, BN 82270, acting as calpain-inhibitor and anti-oxidant. Neuromuscul Disord (2006) 0.92
The alteration of calcium homeostasis in adult dystrophic mdx muscle fibers is worsened by a chronic exercise in vivo. Neurobiol Dis (2004) 0.92
Tumor necrosis factor-alpha (TNF-alpha) regulates shedding of TNF-alpha receptor 1 by the metalloprotease-disintegrin ADAM8: evidence for a protease-regulated feedback loop in neuroprotection. J Neurosci (2010) 0.92
Dramatic improvement of myotonia permanens with flecainide: a two-case report of a possible bench-to-bedside pharmacogenetics strategy. Eur J Clin Pharmacol (2012) 0.91
Pre-clinical trials in Duchenne dystrophy: what animal models can tell us about potential drug effectiveness. Neuromuscul Disord (2002) 0.90
Progressive loss of striatal neurons causes motor dysfunction in MND2 mutant mice and is not prevented by Bcl-2. Exp Neurol (2002) 0.89
Taurine and skeletal muscle disorders. Neurochem Res (2004) 0.89
Mechanism of interaction of niflumic acid with heterologously expressed kidney CLC-K chloride channels. J Membr Biol (2007) 0.89
Optically active mexiletine analogues as stereoselective blockers of voltage-gated Na(+) channels. J Med Chem (2003) 0.89
Antiproliferative and cytotoxic effects of some sigma2 agonists and sigma1 antagonists in tumour cell lines. Naunyn Schmiedebergs Arch Pharmacol (2004) 0.88
4-(tetralin-1-yl)- and 4-(naphthalen-1-yl)alkyl derivatives of 1-cyclohexylpiperazine as sigma receptor ligands with agonist sigma2 activity. J Med Chem (2004) 0.88
On the metabolically active form of metaglidasen: improved synthesis and investigation of its peculiar activity on peroxisome proliferator-activated receptors and skeletal muscles. ChemMedChem (2015) 0.86
Searching for novel anti-myotonic agents: pharmacophore requirement for use-dependent block of skeletal muscle sodium channels by N-benzylated cyclic derivatives of tocainide. Neuromuscul Disord (2011) 0.86
Structure-affinity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinealkylamides, a new class of 5-hydroxytryptamine7 receptor agents. J Med Chem (2004) 0.86
Effect of microgravity on gene expression in mouse brain. Exp Brain Res (2008) 0.86
Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity. J Med Chem (2005) 0.85
Midbrain SERT in degenerative parkinsonisms: a 123I-FP-CIT SPECT study. Mov Disord (2010) 0.85
Combined modifications of mexiletine pharmacophores for new lead blockers of Na(v)1.4 channels. Biophys J (2013) 0.85
Severity of neuropsychiatric symptoms and dopamine transporter levels in dementia with Lewy bodies: a 123I-FP-CIT SPECT study. Mov Disord (2009) 0.84
N-aryl-2,6-dimethylbenzamides, a new generation of tocainide analogues as blockers of skeletal muscle voltage-gated sodium channels. J Med Chem (2014) 0.84
Dualistic actions of cromakalim and new potent 2H-1,4-benzoxazine derivatives on the native skeletal muscle K ATP channel. Br J Pharmacol (2003) 0.84
Involvement of voltage-gated sodium channels blockade in the analgesic effects of orphenadrine. Pain (2009) 0.84